| |
|
|
|
|
|
 |
| |
|
±Û¶óÄÞÁ¤(µðŬ·Î¸£Æä³ª¹Ìµå)
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
693900470[A03600061]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ãȲ»ö ¿øÇüÁ¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
60, 100, 250, 500Á¤ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 50¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806939004704 |
8806939004711 |
|
|
| ÁÖ¼ººÐÄÚµå |
143101ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
(°æ±¸ : Á¤Á¦)
³ì³»Àå
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
(°æ±¸ : Á¤Á¦)
1ÀÏ 50-200mgÀ» 1-4ȸ ºÐÇÒ °æ±¸Åõ¿©ÇÑ´Ù.
Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ºÎ½Å±â´ÉºÎÀü, ¾ÆÄ¡¼Õº´, °£±â´ÉºÎÀü ¹× ½Å±â´ÉºÎÀü ȯÀÚ
2) °í¿°¼ÒÇ÷Áõ¼º ¾Æ½Ãµµ½Ã½º, ü¾×ÁßÀÇ ³ªÆ®·ý, Ä®·ýÀÌ ÇöÀúÈ÷ °¨¼ÒµÇ¾î Àִ ȯÀÚ
3) ½ÉÇÑ ÆóÆó»öÁõ ȯÀÚ
4) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) ´ç´¢º´ ȯÀÚ(¾Æ½Ãµµ½Ã½º°¡ ÀϾ ¼ö ÀÖ´Ù.)
2) È£Èí¼º ¾Æ½Ãµµ½Ã½º ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) Á¤½Å½Å°æ°è : Á¹À½, µÎÅë, ¶§¶§·Î ¾È¸é, »çÁö ±¸° µîÀÇ Áö°¢ÀÌ»ó, ¾îÁö·¯¿ò, ¾ÆÁÖ µå¹°°Ô ¹æÇâ°¨°¢Àå¾Ö, ¿ì¿ï»óÅÂ, ÃÊÁ¶°¨, Á¤½ÅÂø¶õ, À̸í, ½Å°æ°ú¹Î, ÁøÀü, ¿îµ¿½ÇÁ¶, ÀϽÃÀûÀÎ ±Ù½Ã µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼Òȱâ°è : ¶§¶§·Î ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, º¯ºñ, ±¸°¥ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) Ç÷¾× : µå¹°°Ô Ç÷¼ÒÆÇ°¨¼Ò, °ú¸³±¸°¨¼Ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ºñ´¢±â°è : ¶§¶§·Î ½Å¿ä·Î°á¼®, ºó´¢ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) °ú¹ÎÁõ : µå¹°°Ô ¹ßÁø, °¡·Á¿ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ±âŸ : ±ÇÅÂ, ÇǷΰ¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ´ë·®ÀÇ ¾Æ½ºÄÚ¸£ºó»ê°ú º´¿ëÅõ¿©¿¡ ÀÇÇØ ¿ä·Î½Å°á¼®À» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
2) ´ë·®ÀÇ ¾Æ½ºÇǸ°, ź»êÅ»¼ö¼ÒÈ¿¼Ò ÀúÇØÁ¦¿Í º´¿ëÅõ¿©½Ã ½Ä¿åºÎÁø, ºü¸¥ È£Èí, Á¹À½, È¥¼ö µîÀÌ µå¹°°Ô º¸°íµÇ¾ú´Ù.
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: DICHLORPHENAMIDEDARANIDE (DICHLORPHENAMIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Dichlorphenamide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow), although the mechanism by which they do this is not fully understood. Evidence suggests that HCO3- ions are produced in the ciliary body by hydration of carbon dioxide under the influence of carbonic anhydrase and diffuse into the posterior chamber which contains more Na+ and HCO3- ions than does plasma and consequently is hypertonic. Water is then attracted to the posterior chamber by osmosis, resulting in a drop in pressure.
|
| Pharmacology |
Dichlorphenamide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dichlorphenamide is an oral carbonic anhydrase inhibitor indicated for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow).
|
| Metabolism |
Dichlorphenamide¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Dichlorphenamide¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 55%
|
| Half-life |
Dichlorphenamide¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Pharmacokinetics |
DichlorphenamideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë ¹ßÇö ½Ã°£ : °æ±¸ : 1½Ã°£ À̳»
- ÃÖ°í È¿°ú : °æ±¸ : 2-4½Ã°£
- ÀÛ¿ë Áö¼Ó½Ã°£ : 6-12 ½Ã°£
|
| Biotransformation |
Dichlorphenamide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Dichlorphenamide¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Dichlorphenamide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Dichlorphenamide¿¡ ´ëÇÑ Description Á¤º¸ A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. [PubChem]
|
| Drug Category |
Dichlorphenamide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiglaucomic AgentsCarbonic Anhydrase InhibitorsOphthalmics
|
| Smiles String Canonical |
Dichlorphenamide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O
|
| Smiles String Isomeric |
Dichlorphenamide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O
|
| InChI Identifier |
Dichlorphenamide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)/f/h9-10H2
|
| Chemical IUPAC Name |
Dichlorphenamide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4,5-dichlorobenzene-1,3-disulfonamide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|